IRIS
SARACINO, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.386
AS - Asia 5.519
EU - Europa 3.769
SA - Sud America 1.532
AF - Africa 273
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
AN - Antartide 1
Totale 23.496
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.173
SG - Singapore 2.472
BR - Brasile 1.290
CN - Cina 1.053
HK - Hong Kong 1.014
IT - Italia 654
DE - Germania 637
SE - Svezia 613
RU - Federazione Russa 587
VN - Vietnam 441
FI - Finlandia 285
GB - Regno Unito 273
UA - Ucraina 171
FR - Francia 164
CI - Costa d'Avorio 134
CA - Canada 108
ID - Indonesia 107
IN - India 98
AR - Argentina 91
MX - Messico 70
PL - Polonia 66
NL - Olanda 55
BD - Bangladesh 54
AT - Austria 51
BE - Belgio 50
ZA - Sudafrica 50
EC - Ecuador 49
JP - Giappone 41
TR - Turchia 35
ES - Italia 32
IQ - Iraq 31
IE - Irlanda 27
CO - Colombia 26
PK - Pakistan 26
LT - Lituania 23
CZ - Repubblica Ceca 22
VE - Venezuela 22
SA - Arabia Saudita 16
CL - Cile 14
IL - Israele 13
KE - Kenya 13
MA - Marocco 13
PY - Paraguay 13
UZ - Uzbekistan 13
AE - Emirati Arabi Uniti 12
PE - Perù 12
TW - Taiwan 12
JO - Giordania 11
PH - Filippine 11
TN - Tunisia 11
DZ - Algeria 10
HR - Croazia 10
CR - Costa Rica 9
GR - Grecia 9
EG - Egitto 8
RS - Serbia 8
UY - Uruguay 8
KZ - Kazakistan 7
CH - Svizzera 6
JM - Giamaica 6
NP - Nepal 6
HU - Ungheria 5
IR - Iran 5
OM - Oman 5
AU - Australia 4
AZ - Azerbaigian 4
BO - Bolivia 4
BY - Bielorussia 4
ET - Etiopia 4
EU - Europa 4
GH - Ghana 4
HN - Honduras 4
LB - Libano 4
LY - Libia 4
NI - Nicaragua 4
SN - Senegal 4
TT - Trinidad e Tobago 4
UG - Uganda 4
AL - Albania 3
BH - Bahrain 3
KG - Kirghizistan 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
PS - Palestinian Territory 3
PT - Portogallo 3
SV - El Salvador 3
ZW - Zimbabwe 3
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
GY - Guiana 2
LV - Lettonia 2
MD - Moldavia 2
MV - Maldive 2
MW - Malawi 2
MZ - Mozambico 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
RO - Romania 2
SO - Somalia 2
Totale 23.471
Salva come PNG Salva come JPEG
Città #
Fairfield 1.560
Ashburn 1.532
Singapore 1.290
Woodbridge 1.037
Hong Kong 1.009
Houston 768
Chandler 709
Seattle 663
Cambridge 534
Wilmington 513
Ann Arbor 476
Nyköping 472
Dallas 453
Beijing 427
Jacksonville 381
Munich 280
New York 278
Los Angeles 217
Lawrence 180
Roxbury 179
Nanjing 172
Abidjan 134
Helsinki 127
Ho Chi Minh City 120
São Paulo 119
Bari 110
Des Moines 104
Buffalo 98
Princeton 88
Jakarta 82
Boardman 77
Hanoi 76
Dong Ket 68
London 68
Brooklyn 67
Inglewood 65
San Diego 64
Santa Clara 63
Chicago 52
Rome 51
Warsaw 51
Moscow 45
Brussels 44
Frankfurt am Main 44
Turku 42
Hebei 40
Stockholm 39
Rio de Janeiro 38
Montreal 37
Tokyo 37
Milan 36
Nuremberg 36
Shenyang 36
Mexico City 31
Nanchang 31
Toronto 31
Denver 30
Jiaxing 30
Belo Horizonte 28
Curitiba 28
Dublin 27
Johannesburg 27
Atlanta 26
Chennai 26
Tianjin 25
Dearborn 24
Paris 24
San Francisco 22
Brasília 21
Columbus 21
Pune 21
The Dalles 21
Vienna 21
Düsseldorf 20
Poplar 20
Boston 19
Falkenstein 19
Orem 19
Falls Church 18
Guangzhou 18
Phoenix 18
Salt Lake City 18
Taranto 18
Amsterdam 16
Ankara 16
Brno 16
Guayaquil 16
Hải Dương 16
Campinas 15
Haiphong 15
Salvador 15
Da Nang 14
Mumbai 14
Querétaro 14
Council Bluffs 13
Modugno 13
Quito 13
Biên Hòa 12
Lahore 12
Porto Alegre 12
Totale 16.232
Salva come PNG Salva come JPEG
Nome #
Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study 362
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 354
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 341
Economic evaluation of HIV treatments: The I.CO.N.A. cohort study 220
First Case of Paraphimosis as a Severe Complication of Monkeypox 206
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 200
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 170
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 167
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 165
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 162
An outbreak of HIV-1 BC recombinants in Southern Italy 159
Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study 159
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 153
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 153
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 151
A 75-year-old woman presenting with nasal vestibulitis 151
Potential diagnostic properties of chest ultrasound in thoracic tuberculosis—A systematic review 151
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 148
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study 144
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 142
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 142
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 141
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 139
The elderly and direct antiviral agents: Constraint or challenge? 139
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 138
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. 137
Co-receptor switch during HAART is independent of virological success 136
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 136
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 135
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 134
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients 134
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 133
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 131
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study 131
A 75-year-old woman presenting with nasal vestibulitis 130
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 129
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. 128
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 126
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 126
Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique 126
Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review 125
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 125
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents 124
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 123
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin 121
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients 120
Mortality in migrants living with HIV in western Europe (1997-2013): A collaborative cohort study 119
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 118
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 118
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 118
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 118
Incidence of tuberculosis among HIV-Infected patients receiving highly active antiretroviral therapy in Europe and North America 118
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 116
Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010. 116
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 116
Evolution of antiretroviral prescription and response over a period of 8 years: An Italian multicentre observational prospective cohort study 116
Are the proposed env mutations actually associated with resistance to maraviroc? 116
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 115
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors 115
Splenic abscesses as a first manifestation of Crohn's disease: A case report 115
The at risk child clinic (ARCC): 3 years of health activities in support of the most vulnerable children in Beira, Mozambique 115
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? 114
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 114
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 114
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 113
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 112
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 112
Epidemiological multicentric Italian society of infectious and tropical diseases study on prevalence of tropical diseases in hospitalized immigrants in Italy during 2002 111
Direct-acting antivirals for HIV/HCV co-infected individuals: as good as it gets? 111
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 111
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 110
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 110
Tuberculosis and diabetes: Current state and future perspectives 110
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 110
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 109
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 108
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study 108
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women 107
Reproductive choice in individuals HIV-1 infected in South Eastern Italy 107
Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study 107
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 107
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 106
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 106
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study 105
Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe 105
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program 105
Drug Resistance Mutations and Newly Recognized Treatment-Related Substitutions in the HIV-1 Protease Gene: Prevalence and Associations With Drug Exposure and Real or Virtual Phenotypic Resistance to Protease Inhibitors in Two Clinical Cohorts of Antiretroviral Experienced Patients 103
Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A “turning-off” effect of liver inflammation? 102
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. 102
Impact of Ebola outbreak on reproductive health services in a rural district of Sierra Leone: A prospective observational study 102
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs? 101
Pulmonary Artery Filling Defects in Covid-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication? 101
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance and Herpesvirus Reactivation: A Double Face of Janus? 100
Letter: chronic hepatitis C genotype 3 infection - still a hurdle toward a direct-acting anti-viral-induced HCV cure? 99
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 99
Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection 99
"In vitro" spontaneous production of B-chemokines by endocervical and endometrial short-term bioptic cultures 98
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 98
Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives 97
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 97
Totale 13.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.863
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.863
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.171 0 0 0 0 0 113 235 167 168 239 94 155
2021/20221.309 86 158 21 61 52 106 81 91 82 93 183 295
2022/20232.087 316 204 150 143 225 293 39 285 311 18 57 46
2023/20241.149 80 216 68 88 111 277 37 42 28 36 40 126
2024/20254.991 125 93 314 142 99 423 542 516 263 344 656 1.474
2025/20266.939 1.611 791 1.141 1.689 1.530 177 0 0 0 0 0 0
Totale 24.724